CROOZ
16.5.2023 05:01:27 CEST | Business Wire | Press release
CROOZ, Inc. (listed on the Tokyo Stock Exchange Standard Market: 2138; head office: Shibuya-ku, Tokyo; the President and CEO: Koji Obuchi; hereinafter "CROOZ") announced that it has officially launched PROJECT XENO, an NFT game developed by the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005017/en/
XENO_TOP (Graphic: Business Wire)
About PROJECT XENO
PROJECT XENO is a blockchain game operated by EPOCH FACTORY and developed by CROOZ, a listed Japanese company. The full-scale tactical battle NFT game combines GameFi, e-Sports, and Fun. PROJECT XENO is available globally and can be played on smartphones and PCs.
PROJECT XENO has the following features.
Feature (1) Collaboration with celebrities such as Floyd Mayweather JR
The game has appointed some ambassadors to reach users around the world; popular YouTuber Hikaru as an ambassador in Japan, along with eight-division boxing world champion Manny Pacquiao and Fumiya, "the most famous Japanese in the Philippines," as ambassadors in Southeast Asia. In addition, NFTs collaborated with former five-division boxing world champion Floyd Mayweather Jr. and others are also available.
Feature (2) Developed by a listed Japanese company
PROJECT XENO is developed and operated by a listed company that has released many hit smartphone games in the Japanese market and is able to provide high-quality games and stable operations.
Feature (3) “Web 2.5” specifications that also enable users without NFT to play
PROJECT XENO is a free-to-play game, meaning that it can still be played by users who do not own NFT. Furthermore, the game supports in-game purchases, allowing users to play the game in exactly the same way as NFT holders. The only difference with NFT holders is the presence or absence of the Earn feature. There are no discrepancies in character strength, etc., allowing PROJECT XENO to be played like any other social game. If social games are Web 2.0 and GameFi games are Web 3.0, then PROJECT XENO can be considered a Web 2.5 game.
About GXE tokens
GXE is a token distributed on PROJECT XENO. GXE is listed on MEXC Global, LBank, BKEX, Bittrex Global, and Gate.io. On May 16, 2023 (Japan time), it was also listed on BITPoint, a crypto asset exchange of the SBI Group based in Tokyo, Japan. BITPoint has been approved as a crypto asset exchange operator by the Japanese Financial Services Agency.
The latest information on PROJECT XENO
For more information on PROJECT XENO, visit the website.
Up-to-date information is also available on Twitter.
- PROJECT XENO: http://project-xeno.com/
- PROJECT XENO Official Twitter: https://twitter.com/PROJECTXENO_GLB
About CROOZ, Inc.
With the fashion shopping site "SHOPLIST.com by CROOZ" at its core, CROOZ, Inc. develops a wide range of Internet services in the entertainment domain, including shopping and games, always in step with the changing times.
https://crooz.co.jp
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005017/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom